CALGARY, Aug. 2, 2016 /CNW/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") announced today that it has changed its name to Zenith Capital Corp. concurrent with the internal corporate reorganization which the Company has determined will be effective on August 1, 2016. The name change and reorganization were approved by shareholders at the annual and special meeting of shareholders held on January 7, 2016.
The reorganization results in the transfer of the Company's principal operating assets to Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., in exchange for additional common shares of Zenith Epigenetics Ltd. Zenith Capital Corp. retains its investment in the royalty preferred shares of Resverlogix Corp. As Zenith Capital Corp. owns all of the securities of Zenith Epigenetics Ltd., there is no immediate change in the ultimate beneficial ownership of the operating assets.
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.'s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer ("mCRPC").
SOURCE Zenith Capital Corp.
For further information: Donald McCaffrey, President and Chief Executive Officer, Zenith Capital Corp., Phone: 587-390-7865, Email: firstname.lastname@example.org